- Home
- VIGL vs APLT Comparison
VIGL vs APLT Comparison
Compare VIGL & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- APLT
- Stock Information
- Founded
- VIGL 2020
- APLT 2016
- Country
- VIGL United States
- APLT United States
- Employees
- VIGL N/A
- APLT N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- APLT Health Care
- Exchange
- VIGL Nasdaq
- APLT Nasdaq
- Market Cap
- VIGL 74.7M
- APLT 37.5M
- IPO Year
- VIGL 2022
- APLT 2019
- Fundamental
- Price
- VIGL $2.41
- APLT $0.41
- Analyst Decision
- VIGL Strong Buy
- APLT Buy
- Analyst Count
- VIGL 5
- APLT 7
- Target Price
- VIGL $16.33
- APLT $6.10
- AVG Volume (30 Days)
- VIGL 164.4K
- APLT 1.9M
- Earning Date
- VIGL 05-07-2025
- APLT 05-20-2025
- Dividend Yield
- VIGL N/A
- APLT N/A
- EPS Growth
- VIGL N/A
- APLT N/A
- EPS
- VIGL N/A
- APLT N/A
- Revenue
- VIGL N/A
- APLT $455,000.00
- Revenue This Year
- VIGL N/A
- APLT $1,768.13
- Revenue Next Year
- VIGL N/A
- APLT $361.28
- P/E Ratio
- VIGL N/A
- APLT N/A
- Revenue Growth
- VIGL N/A
- APLT N/A
- 52 Week Low
- VIGL $1.31
- APLT $0.30
- 52 Week High
- VIGL $6.06
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- VIGL 60.07
- APLT 48.67
- Support Level
- VIGL $1.75
- APLT $0.39
- Resistance Level
- VIGL $3.00
- APLT $0.49
- Average True Range (ATR)
- VIGL 0.26
- APLT 0.04
- MACD
- VIGL 0.08
- APLT 0.01
- Stochastic Oscillator
- VIGL 55.30
- APLT 55.40
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.